Neurology's New Frontier: IV CBD Enters the Clinic Amid Scrutiny

WESTLAKE VILLAGE, CA – January 13, 2026 – In a serene, lakeside setting typically associated with restorative retreats, a California neurology clinic is pioneering a new and controversial application for cannabidiol (CBD). BrainThrive, PC, a neurology and diagnostic center, has partnered with sterile CBD innovator PICO IV to offer intravenous CBD infusions under the direct supervision of a neurologist. The collaboration aims to provide a controlled environment for measuring the effects of CBD on the nervous system, particularly for high-achieving professionals who struggle to disconnect from the pressures of modern life.

This initiative places PICO IV's patented sterile CBD solution at the center of a novel protocol that blends clinical measurement with high-end wellness. While proponents herald it as the next step in understanding cannabinoid science, the venture operates in a complex regulatory landscape where federal authorities have expressed significant concerns about injectable CBD products.

A Clinical Approach to a Calmer Nervous System

BrainThrive's program is designed for a specific clientele: individuals who function at a high level professionally but report an inability to fully disengage their minds and bodies. According to the clinic, these patients are not seeking a simple spa treatment but a structured, data-driven experience to observe how their nervous system responds to a state of deep rest.

"Neurology has traditionally focused on disease and injury," stated Dr. BJ Adrezin, Co-Founder and CEO of BrainThrive, PC, in a press release. "What's emerging now is interest in how the nervous system behaves under sustained cognitive and sensory demand—and what can be observed when conditions allow it to truly settle."

At the Westlake Village location, the experience is meticulously curated. Patients receive CBD infusions while seated in deep-tissue massage chairs that overlook a lake. The clinic deliberately controls environmental factors such as lighting, sound, and pacing to create a calming atmosphere conducive to nervous system regulation. Central to their methodology is the collection of both subjective and objective data. Patients undergo neurological assessments before and after each session, allowing clinicians to compare patient-reported feelings of calm or focus with measurable changes in nervous-system patterns. This data, including patient-reported outcomes and neurological indicators, is systematically captured using the AdvancedMD electronic health record platform.

This focus on data collection is positioned as a contribution to the evolving scientific conversation around cannabinoids. Dr. Adrezin emphasized the clinic's role: "Our role is to observe carefully, measure consistently, and contribute data to a conversation that's rapidly evolving."

The Technology Behind the Infusion

The collaboration hinges on the unique delivery system developed by Sacramento-based PICO IV. The company claims to have created the world's first sterile CBD solution, a critical feature for any product administered intravenously. This is achieved through what PICO IV describes as patented and patent-pending "pico-emulsion technology."

This process reportedly reduces CBD particles to a picometer size—a scale one thousand times smaller than the more common nano-emulsions. According to the company, this microscopic particle size allows the CBD to be fully dissolved in a water-based solution and passed through a sterile filter, a process designed to eliminate contaminants and ensure purity for IV use. The primary advantage of intravenous delivery is its bioavailability. By introducing CBD directly into the bloodstream, the method bypasses the digestive system and first-pass metabolism in the liver, processes that can significantly reduce the amount of CBD that ultimately reaches the body's systems when taken orally. This allows for what the company claims is nearly 100% absorption and precise, consistent dosing.

"By combining our delivery technology with their clinical oversight, we're able to document patient experiences in a way that's much more meaningful than just anecdotal feedback," said Joe Young, CEO and founder of PICO IV. "They bring a level of neurological expertise that's rare in this space."

Navigating a Complex Regulatory Landscape

While the collaboration between PICO IV and BrainThrive is framed as a clinical initiative to gather "real-world evidence" (RWE), it operates within a challenging and uncertain federal regulatory framework. The 2018 Farm Bill legalized hemp-derived CBD at the federal level, but the U.S. Food and Drug Administration (FDA) retains authority over how CBD can be marketed, especially when medical claims are made.

The FDA's position is that any product intended for therapeutic use, such as treating a disease or affecting the body's function, is classified as a drug and requires extensive clinical trials and formal approval. To date, Epidiolex is the only cannabis-derived drug the FDA has approved. The agency has been particularly stringent regarding injectable CBD products, which pose heightened safety risks as they bypass the body's natural defenses.

In fact, the FDA has previously issued a warning letter to Pico IV Inc. regarding its injectable CBD product, citing it as an unapproved new drug in violation of the Federal Food, Drug, and Cosmetic Act. The agency has consistently warned companies against marketing CBD products with unproven health claims. The partnership with BrainThrive and its emphasis on data collection under neurologist guidance appears to be a strategic effort to build a body of evidence that could support future regulatory submissions. The press release explicitly aligns the initiative with a December 19 Executive Order directing federal agencies to prioritize RWE for cannabinoid research, suggesting a long-term strategy aimed at legitimizing their approach through structured data gathering outside of a formal, FDA-registered clinical trial.

This positions the BrainThrive program in a gray area—it is not a formal clinical trial, but a "clinical initiative" generating data that the companies hope will validate their technology and its applications. For now, the program is active at the Westlake Village clinic, pushing the boundaries of both neurological wellness and cannabinoid regulation. The success of this model may ultimately depend on whether the evidence they gather is compelling enough to satisfy scientists, consumers, and, most importantly, federal regulators.